Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Refractory Malignancy”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 0 results

Testing effectiveness (Phase 2)Active Not RecruitingNCT06390865
What this trial is testing

Testing MLN0128 (TAK-228) as Potentially Targeted Treatment in Cancers With TSC1 or TSC2 Genetic Changes (MATCH - Subprotocol M)

Who this might be right for
Advanced LymphomaAdvanced Malignant Solid NeoplasmRefractory Lymphoma+2 more
National Cancer Institute (NCI) 49
Early research (Phase 1)Looking for participantsNCT07439211
What this trial is testing

Assessing PI3K Gamma Inhibition With Azacitidine, Venetoclax and Eganelisib in Patients With Acute Myeloid Leukemia

Who this might be right for
Leukemia, MyeloidLeukemiaAcute Myeloid Leukemia+1 more
Jacqueline Garcia, MD 48
Early research (Phase 1)Study completedNCT03309111
What this trial is testing

Study of ISB 1342, a CD38/CD3 Bispecific Antibody, in Subjects With Previously Treated Multiple Myeloma

Who this might be right for
Relapsed/Refractory Multiple Myeloma
Ichnos Sciences SA 81
Early research (Phase 1)Active Not RecruitingNCT05359445
What this trial is testing

IMA401 TCER® in Recurrent and/or Refractory Solid Tumors, Alone or in Combination With a Checkpoint Inhibitor

Who this might be right for
Refractory CancerRecurrent CancerSolid Tumor, Adult+1 more
Immatics Biotechnologies GmbH 95
Early research (Phase 1)Looking for participantsNCT05054257
What this trial is testing

CART19 Cells Effects in Patients with Relapsed or Refractory Acute Lymphoblastic Leukemia and Non-Hodgkin's Lymphoma

Who this might be right for
Relapsed or Refractory B-cell Acute Lymphoblastic LeukemiaNon-Hodgkin's Lymphoma RefractoryNon-Hodgkin's Lymphoma, Relapsed
Institute of Hematology and Blood Transfusion, Czech Republic 10
Not applicableLooking for participantsNCT06111612
What this trial is testing

Intensive Conditioning withTHI/Bu/Flu/Ara-C in Allo-HSCT for Myeloid Malignancies With Extramedullary Involvement

Who this might be right for
Acute Myeloid LeukemiaMyelodysplastic NeoplasmChronic Myelomonocytic Leukemia+2 more
Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine 50
Early research (Phase 1)Study completedNCT00040781
What this trial is testing

Gefitinib in Treating Children With Refractory Solid Tumors

Who this might be right for
Unspecified Childhood Solid Tumor, Protocol Specific
National Cancer Institute (NCI) 45
Early research (Phase 1)WithdrawnNCT06007911
What this trial is testing

Venetoclax-Navitoclax With Cladribine-based Salvage Therapy in Patients With Relapsed/Refractory Acute Myeloid Leukemia

Who this might be right for
Relapsed Adult AMLRefractory AML
Medical College of Wisconsin
Testing effectiveness (Phase 2)Active Not RecruitingNCT04439136
What this trial is testing

Testing Afatinib as a Potential Targeted Treatment in Cancers With HER2 Genetic Changes (MATCH-Subprotocol B)

Who this might be right for
Advanced LymphomaAdvanced Malignant Solid NeoplasmHematopoietic and Lymphoid Cell Neoplasm+3 more
National Cancer Institute (NCI) 40
Early research (Phase 1)Study completedNCT05950334
What this trial is testing

FT522 With Rituximab in Relapsed/Refractory B-Cell Lymphoma (FT522-101)

Who this might be right for
Relapsed/Refractory B-Cell Lymphoma
Fate Therapeutics 20
Not applicableNot Yet RecruitingNCT07717164
What this trial is testing

PRAISE-IR Versus CIBMTR Controls

Who this might be right for
ALL (Acute B-Lymphoblastic Leukemia)AML (Acute Myeloid Leukemia)MDS (Myelodysplastic Syndrome)
Miltenyi Biomedicine GmbH 51
Early research (Phase 1)Active Not RecruitingNCT04608487
What this trial is testing

Axi-cel in CNS Lymphoma

Who this might be right for
LymphomaLymphoma Cns
Dana-Farber Cancer Institute 18
Testing effectiveness (Phase 2)Study completedNCT01369849
What this trial is testing

Akt Inhibitor MK2206, Bendamustine Hydrochloride, and Rituximab in Treating Patients With Relapsed Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

Who this might be right for
Chronic Lymphocytic LeukemiaRecurrent Small Lymphocytic LymphomaRefractory Chronic Lymphocytic Leukemia
National Cancer Institute (NCI) 15
Early research (Phase 1)Study completedNCT00346255
What this trial is testing

BB-10901 in Treating Patients With Relapsed and/or Refractory Multiple Myeloma

Who this might be right for
Multiple Myeloma
ImmunoGen, Inc. 37
Early research (Phase 1)Study completedNCT03143985
What this trial is testing

Vactosertib in Combination w/ Pomalidomide in Relapsed or Relapsed and Refractory Multiple Myeloma

Who this might be right for
Multiple Myeloma
Koen van Besien 18
Testing effectiveness (Phase 2)Study completedNCT05175404
What this trial is testing

Use of 18F-PSMA-11 PET for Detection of Lesions in Iodine Refractory Thyroid Cancers

Who this might be right for
Thyroid Cancer
University Hospital, Ghent 8
Large-scale testing (Phase 3)Study completedNCT04182204
What this trial is testing

Evaluate the Safety and Efficacy of Polatuzumab Vedotin in Combination With Rituximab, Gemcitabine and Oxaliplatin Compared to Rituximab, Gemcitabine and Oxaliplatin Alone in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma

Who this might be right for
Diffuse Large B-Cell Lymphoma
Hoffmann-La Roche 270
Testing effectiveness (Phase 2)Study completedNCT00051116
What this trial is testing

A Phase II Study of Continuous Versus Syncopated Dosing of CC-5013 for the Treatment of Refractory Multiple Myeloma

Who this might be right for
Multiple Myeloma
Celgene Corporation 100
Early research (Phase 1)Study completedNCT00854152
What this trial is testing

A Study Evaluating GDC-0980 Administered Once Daily in Patients With Refractory Solid Tumors or Non-Hodgkin's Lymphoma

Who this might be right for
Non-Hodgkin's Lymphoma, Solid Cancers
Genentech, Inc. 121
Not applicableStudy completedNCT03389347
What this trial is testing

High Throughput Drug Sensitivity and Genomics Data in Developing Individualized Treatment in Patients With Relapsed or Refractory Multiple Myeloma or Plasma Cell Leukemia

Who this might be right for
Plasma Cell LeukemiaRecurrent Multiple MyelomaRefractory Multiple Myeloma
University of Washington 40
Next Page